de Sa Dantas Bezerra D, et al. - In this prospective, randomized, single-blind study, authors examined comparatively, 300 U vs 500 U of abobotulinumtoxinA (ABO) intravesical injections for the treatment of idiopathic overactive bladder (OAB) refractory to first and second-line treatments among 21 candidates. They noticed an increase of maximum cistometric capacity (MCC) from 185.0 to 270.9 mL (300 U) and from 240.8 to 311.7 mL (500 U), comparing the baseline with 12 weeks, without statistical difference between the groups. They noted no episodes of incontinence with 500 U at week 24. Overall, they concluded improvement in symptoms and quality of life for a longer period of time with intravesical ABO injection at 500 U.